Secondary Stock OfferingsBy The Online Investor Staff, updated Mon., Jan. 24, 11:32 AM
|This Slide: #12 of 25|
Slide #12. Intra-Cellular Therapies, Inc. — Secondary Offering
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies. -updated 1/4- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,428,571 shares on the same terms and conditions. The offering is expected to close on January 7, 2022, subject to the satisfaction of customary closing conditions.
Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA (lumateperone) has been approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. Co. is developing ITI-1284 for the treatment of behavioral disturbances in patients with dementia, the treatment of dementia-related psychosis and for the treatment of certain depressive disorders in the elderly.
ITCI SEC Filing Email Alerts Service
Open the ITCI Page at The Online Investor »
Free ITCI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Strong Buy (3.71 out of 4)